Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 5Melanoma 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 4Paclitaxel 3Bevacizumab 3fludarabine 2Nivolumab 2Drug Therapy 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1spartalizumab 1sapanisertib 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1ridaforolimus 1regorafenib 1pazopanib 1motexafin gadolinium 1lenvatinib 1epacadostat 1cobimetinib 1cediranib 1cc-486 1carboxyamido-triazole 1aflibercept 1abiraterone 1Uncertainty 1Sirolimus 1Quality of Life 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × epacadostat × Gynecologic × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡